Anti-Kininogen 1抗体(ab97761)


  • 产品名称Anti-Kininogen 1抗体
    参阅全部 Kininogen 1 一抗
  • 描述
    兔多克隆抗体to Kininogen 1
  • 经测试应用适用于: WB, IHC-P, ICC/IFmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    Recombinant fragment, corresponding to amino acids 10-426 of Human Kininogen 1

  • 阳性对照
    • 293T, A431, H1299, HeLa, HepG2, MOLT4 or Raji cell line.



Our Abpromise guarantee covers the use of ab97761 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
WB 1/500 - 1/3000. Predicted molecular weight: 48 kDa.
IHC-P 1/100 - 1/500.
ICC/IF 1/100 - 1/200.


  • 功能(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
  • 组织特异性Secreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
  • 疾病相关Defects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
  • 序列相似性Contains 3 cystatin domains.
  • 翻译后修饰Bradykinin is released from kininogen by plasma kallikrein.
    Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
    Phosphorylation sites are present in the extracelllular medium.
    N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
  • 细胞定位Secreted > extracellular space.
  • Information by UniProt
  • 数据库链接
  • 别名
    • Alpha-2-thiol proteinase inhibitor antibody
    • BDK antibody
    • Bradykinin included antibody
    • Fitzgerald factor antibody
    • FLAUJEAC FACTOR antibody
    • High molecular weight kininogen antibody
    • HMWK antibody
    • Ile-Ser-Bradykinin antibody
    • Kallidin I antibody
    • Kallidin II antibody
    • KNG antibody
    • KNG1 antibody
    • KNG1_HUMAN antibody
    • Low molecular weight growth-promoting factor antibody
    • WILLIAMS FACTOR antibody
    • Williams-Fitzgerald-Flaujeac factor antibody
    see all

Anti-Kininogen 1 antibody 图像

  • Anti-Kininogen 1 antibody (ab97761) at 1/1000 dilution + MOLT4 whole cell lysate at 30 µg

    Predicted band size : 48 kDa
  • ab76197 at 1/200 dilution staining Kininogen in paraformaldehyde-fixed HeLa cells by immunofluorescence .
    Lower image is merged with DNA probe.
  • ab97761 at 1/500 dilution staining Kininogen in paraffin-embedded A549 xenograft tissue by immunohistochemistry.

Anti-Kininogen 1 antibody (ab97761)参考文献

ab97761 has not yet been referenced specifically in any publications.

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Human Cell lysate - whole cell (Raji, CLL B-lymphocytes,T47D,SW837)
Loading amount 20 µg
Specification Raji, CLL B-lymphocytes,T47D,SW837
Gel Running Conditions Reduced Denaturing (12 %)
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 21°C

Dr. Elena Kashuba

Verified customer

提交于 Apr 10 2013